tirzepatide for cardiovascular disease Obesity and heart failure: what changes with tirzepatideBlog barnaclínic+ How Tirzepatide Supports Cardiovascular Health

It all depends on your starting weight and other measures you take in your weight management journey

Tirzepatide: GLP-1 + GIP dual agonist

MiyashitaMKogaKIzumiGSueFMakabeTTaguchiAet al

15,16 Jennings et al 15 demonstrated a significant decrease in weight (6.5 kg), HS Physicians Global Assessment (HS-PGA) (from 4 to 1), DLQI (from 24 to 14), and analgesic use (from daily to not daily) but no decrease in CRP (from 3 mg/dL) after eight weeks of treatment

What we do not know No studies have examined semaglutide exposure through breast milk for more than 9 weeks

Since semaglutide typically produces 10-15% weight loss, many users experience significant improvement in urinary symptoms over time